Patents Represented by Attorney, Agent or Law Firm Kathleen Madden Williams
-
Patent number: 6548250Abstract: The invention relates to a method of generating a signal indicative of the presence of a target nucleic acid sequence in a sample, where the method includes forming a cleavage structure by incubating a sample containing a target nucleic acid sequence with a nucleic acid polymerase and cleaving the cleavage structure with a FEN nuclease to generate a cleaved nucleic acid fragment. The invention also relates to methods of detecting or measuring a target nucleic acid sequence, where the method includes forming a cleavage structure by incubating a target nucleic acid sequence with a nucleic acid polymerase, cleaving the cleavage structure with a FEN nuclease and detecting or measuring the release of a fragment.Type: GrantFiled: August 30, 2000Date of Patent: April 15, 2003Assignee: StratageneInventor: Joseph A. Sorge
-
Patent number: 6528254Abstract: The invention relates to a method of generating a signal indicative of the presence of a target nucleic acid sequence in a sample, where the method includes forming a cleavage structure by incubating a sample containing a target nucleic acid sequence with a nucleic acid polymerase and cleaving the cleavage structure with a FEN nuclease to generate a cleaved nucleic acid fragment. The invention also relates to methods of detecting or measuring a target nucleic acid sequence, where the method includes forming a cleavage structure by incubating a target nucleic acid sequence with a nucleic acid polymerase, cleaving the cleavage structure with a FEN nuclease and detecting or measuring the release of a fragment.Type: GrantFiled: October 29, 1999Date of Patent: March 4, 2003Assignee: StratageneInventor: Joseph A. Sorge
-
Patent number: 6503504Abstract: Disclosed herein is a method of delivering a bioactive compound to an organism that involves growing individual cells in vitro under conditions that allow the formation of an organized tissue, at least a subset of the cells containing a foreign DNA sequence which mediates the production of the bioactive compound; and implanting the organized tissue into the organism, whereby the bioactive compound is produced and delivered to the organism.Type: GrantFiled: July 17, 1997Date of Patent: January 7, 2003Assignee: Miriam HospitalInventor: Herman H. Vandenburgh
-
Patent number: 6489103Abstract: The invention relates to a method for isolating one or more genetic elements encoding a gene product having a desired activity, comprising the steps of: (a) compartmentalising genetic elements into microcapsules; (b) expressing the genetic elements to produce their respective gene products within the microcapsules; (c) sorting the genetic elements which produce the gene product having a desired activity. The invention permits the in vitro evolution of nucleic acids by repeated mutagenesis and iterative applications of the method of the invention.Type: GrantFiled: December 16, 1999Date of Patent: December 3, 2002Assignee: Medical Research CouncilInventors: Andrew Griffiths, Dan Tawfik
-
Patent number: 6479279Abstract: The invention relates to a recombinant vector for stable persistence of exogenous DNA in a eukaryotic cell, and the uses of the recombinant vector for long-term stable production of gene product in the host cell, the vector including the minichromosomal maintenance element of papillomavirus.Type: GrantFiled: September 28, 1998Date of Patent: November 12, 2002Assignee: Estonian BiocentreInventor: Mart Ustav
-
Patent number: 6469228Abstract: Disclosed are isolated transposable elements, or isolated DNA sequences which encode a transposase protein (or a portion of a transposase protein), The isolated transposable elements or the isolated DNA sequences being characterized by the ability to hybridize to the DNA sequence of Minos 1 under stringent hybridization conditions. The invention also relates to a purified transposase protein, or peptide fragments thereof, encoded by such DNA sequences. Such transposable are useful in methods for the stable introduction of a DNA sequence of interest into a eukaryotic cell. The sequence information disclosed herein is useful in the design of oligonucleotide primers which are useful for the isolation of related members of the Tc-1 family of transposable elements.Type: GrantFiled: May 9, 1994Date of Patent: October 22, 2002Assignee: Minos BiosystemsInventors: Charalambos Savakis, Gerald H. Franz, Athanasios Loukeris
-
Patent number: 6448375Abstract: A peptide has an amino acid sequence having more than 80% homology with the amino acid sequence listed as SEQ ID NO:4. A nucleic acid molecule has more than 80% homology with one of the nucleic acid sequences listed as SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3. Ligands, anti-ligands, cells vectors relating to the peptide and/or nucleic acid molecule are also used.Type: GrantFiled: April 9, 1997Date of Patent: September 10, 2002Assignee: Euroscreen S.A.Inventors: Michel Samson, Marc Parmentier, Gilbert Vassart, Frederick Libert
-
Patent number: 6447798Abstract: Water unstable bioadhesive compositions comprising an aqueous plasticiser, a cross-linking agent, a copolymer of a hydrophilic unsaturated water soluble firt monomer a hydrophobic unsaturated water-soluble second monomer, characterised in that they have: (i) a water activity of from 0.4 to 0.9; (ii) an elastic modulus at 1 rad/s of from 700 to 15,000 Pa; (iii) an elastic modulus at 100 rad/s of from 20000 to 40,000 Pa; (iv) a viscous modulus at 1 rad/s of from 400 to 14,000 PA; (v) a viscous modulus at 100 rad/s of from 1000 to 35,000 Pa; wherein the viscous modulus is less than the elastic modulus in frequency range of from 1 to 100 rad/s; amd wound dressings made from them.Type: GrantFiled: January 26, 2001Date of Patent: September 10, 2002Assignee: First Water LimitedInventors: Hugh Semple Munro, Mohammed Yasin
-
Patent number: 6403080Abstract: Disclosed are methods and compositions wherein opsonin-enhanced cells, that is, cells which have been 1) modified so as to express an opsonin from a recombinant nucleic acid, 2) modified so as to express higher levels of an endogenous opsonin, or 3) mixed with an exogenous opsonin, when administered to a subject, modulate the immune response in the recipient to a selected antigen or antigens contained in or attached to the cells.Type: GrantFiled: June 24, 1999Date of Patent: June 11, 2002Assignee: Whitehead Institute for Biomedical ResearchInventor: Andrew H. Segal
-
Patent number: 6395891Abstract: The invention relates to an isolated nucleic acid comprising two operatively linked binding sites for HIV Rev protein, the sites comprising a nucleation motif and an oligomerization motif, wherein the nucleic acid binds Rev protein monomers with a higher degree of cooperativity than wild-type RRE.Type: GrantFiled: September 11, 1998Date of Patent: May 28, 2002Assignee: RiboTargets LimitedInventors: Jonathan Karn, Rodney Warren Zemmel, Peter Jonathan Gasking Butler, Roger K. Craig, Alistair Simpson Irvine
-
Patent number: 6225045Abstract: The invention relates to an isolated nucleic acid comprising two operatively linked binding sites for HIV Rev protein, the sites comprising a nucleation motif and an oligomerization motif, wherein the nucleic acid binds Rev protein monomers with a higher degree of co-operativity than wild-type RRE.Type: GrantFiled: April 15, 1997Date of Patent: May 1, 2001Assignee: Ribotargets, Ltd.Inventors: Jonathan Karn, Rodney Warren Zemmel, Peter Jonathan Gasking Butler, Roger K. Craig, Alistair Simpson Irvine
-
Patent number: 5786145Abstract: A synthetic molecule comprises at least one oligonucleotide comprising an RNA binding sequence or sequences corresponding to the site bound by the HIV protein rev and capable of binding to rev within cells. The binding sequence or sequences, by binding rev within cells, can act to cause inhibition of growth of any HIV present in the cells, and so has potential therapeutic use in treatment of patients infected with HIV. The invention also provides an assay for identifying compounds that inhibit rev binding.Type: GrantFiled: October 10, 1995Date of Patent: July 28, 1998Assignee: Medical Research CouncilInventors: Jonathan Karn, Michael John Gait, Shaun Heaphy, Colin Dingwall
-
Patent number: 5770216Abstract: The invention features a conductive polymer comprising a polymer and zinc oxide particles having a substantially rod shape.Type: GrantFiled: May 17, 1995Date of Patent: June 23, 1998Inventors: Mark Mitchnick, Mamoun Muhammed
-
Patent number: 5756788Abstract: A process for making metal oxide hydrophobic by coating the metal oxide with a silicone polymer is disclosed. The hydrophobic metal oxide is prepared by contacting the metal oxide with a reactive silicone compound and then in a subsequent step the coated metal oxide is heated to 40.degree. to 100.degree. C. for between 1 and 10 hours. The resulting metal oxide is hydrophobic, non-reactive, not affected by water and can be applied to the skin for protection from ultraviolet light of the sun.Type: GrantFiled: October 7, 1996Date of Patent: May 26, 1998Assignees: SunSmart, Inc., Siltech, Inc.Inventors: Mark A. Mitchnick, Anthony J. O'Lenick
-
Patent number: 5723287Abstract: We have made retrovirus particles displaying a functional antibody fragment. We fused the gene encoding an antibody fragment directed against a hapten with that encoding the viral envelope protein (Pr80env) of the ecotropic Moloney murine leukemia virus. The fusion gene was co-expressed in ecotropic retroviral packaging cells with a retroviral plasmid carrying the neomycin phosphotransferase gene (neo), and retroviral particles with specific hapten biding activities were recovered. Furthermore the hapten-binding particles were able to transfer the neo gene and the antibody-envelope fusion gene to mouse fibroblasts. In principle, the display of antibody fragments on the surface of recombinant retroviral particles could be used to target virus to cells for gene delivery, or to retain the virus in target tissues, or for the construction of libraries of viral display packages.Type: GrantFiled: May 3, 1995Date of Patent: March 3, 1998Assignee: Medical Research CouncilInventors: Stephen J. Russell, Robert E. Hawkins, Gregory P. Winter